Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001209191-19-008782
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-02-08 20:14:42
Reporting Period:
2019-02-07
Accepted Time:
2019-02-08 20:14:42
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1649989 Outlook Therapeutics Inc. OTLK () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1230484 A Lawrence Kenyon C/o Oncobiologics, Inc.
7 Clarke Drive
Cranbury NJ 08512
Ceo, Pres, Cfo, Treas & Secy Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-02-07 25,000 $0.90 82,213 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
Footnotes
  1. The purchases reported in this Form 4 were matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, with the Reporting Person's sales of shares at $0.89 per share on September 18, 2018 to cover withholding taxes, as reported on the Reporting Person's Form 4 filed with the Securities and Exchange Commission on September 18, 2018. The Reporting Person has paid to the Issuer $8.19, which represents the full amount of the profit realized in connection with this short-swing transaction, less transaction costs.
  2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.8823 - $0.8952, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.